10rx vs EverFit Medical
An in-depth comparison of two leading GLP-1 Providers
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Two GLP-1 Providers chasing the same patients, trading off price, geography and what lands in the box differently. On our scoring, EverFit Medical opens cheaper — free against $99.67, and 10rx finishes ahead, 8.1 to 4.0. What follows: the prices, what each plan actually covers, the six-dimension score, where each one is weak, and who should pick which.
Pricing
10rx
Compounded; GLP-1 options as low as under $100/mo
Compounded GLP-1 + GIP
EverFit Medical
What’s included
10rx
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
EverFit Medical
Inclusions not disclosed.
Score breakdown
Both providers are scored on the same six-dimension framework. The gradient bar marks the stronger side on each dimension.
10rx
8.1/10
EverFit Medical
4.0/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
Features & Coverage
| Feature | 10rx | EverFit Medical |
|---|---|---|
| Starting Price | $99.67/mo | ✓$0/mo |
| Features | 8 features | 8 features |
| States Available | Not disclosed | Not disclosed |
| Compounded | — | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
About 10rx
10rx sets flat monthly rates on compounded GLP-1: semaglutide at $99.67, tirzepatide at $149.67, with NAD+ and sermorelin sold separately for energy and recovery. A free health quiz online reaches a board-certified telehealth doctor, who reads your history before writing anything, and licensed pharmacy partners handle discreet delivery. The company states it reaches every one of the 50 states. What it does not state is its operating company, its pharmacies, or any terms page.
Read our full 10rx review →About EverFit Medical
Prices are absent from the public site. EverFit Medical is owned by Carrie Zatelli and runs as a hybrid in Ohio: a Macedonia clinic doing body-composition scans, red-light therapy and consultations in person, plus a GLP-1 telehealth track that reaches the whole country. A plan takes in the medical evaluation, the treatment plan, GLP-1 medication where appropriate, nutrition coaching if wanted, and webinars each month. Naming an owner and posting an address is more than this segment usually offers.
Read our full EverFit Medical review →Pros & Cons
10rx
What we like
- Semaglutide at $99.67 a month, 47% below the $189 median for the same drug and form across this register
- Tirzepatide at $149.67 a month, 44% below the $267 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly figure covers medication, consult, shipping
- No FDA warning letter matched this operator when we searched our enforcement register
Watch-outs
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
EverFit Medical
What we like
- No FDA warning letter matched this operator when we searched our enforcement register
- A live video visit with a clinician is required before a prescription, which is slower than a form and is the more careful intake
Watch-outs
- No price appears until the medical intake is complete, so the cost cannot be compared before health information is submitted
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
10rx takes it, 8.1 against 4.0, and it is especially strong on semaglutide at $99.67/month, 47% under the register median. EverFit Medical is no weak second.
Choose 10rx if…
You want semaglutide at $99.67/month, 47% under the register median and an opening price near $99.67 a month.
Choose EverFit Medical if…
You want the lower starting price and a free way to start.
Ready to start? Vetted GLP-1 providers
Vetted telehealth providers that prescribe GLP-1 online.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Trimi Health
Knowing which pharmacy fills the vial — it names VialsRx
From $99/mo
Get started →Strut Health
Semaglutide at $99/month, 48% under the register median
From $99/mo
Get started →Oak
Semaglutide at $119/month, 37% under the register median
From $119/mo
Get started →10rx vs EverFit Medical: FAQ
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Related comparisons
Continue exploring 10rx and EverFit Medical head-to-heads in the same category.
- 10rx vs Trimi Health
- 10rx vs Embody
- 10rx vs He & She MD
- EverFit Medical vs Lean Meds
- EverFit Medical vs NextMeds
- EverFit Medical vs bmiMD
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.